Expanding on their long-standing macrocyclic peptide discovery alliance between the two companies since 2012, Japan-based PeptiDream announced last week that their proprietary Peptide Discovery Platform System (PDPS) technology will be used to identify novel macrocyclic/constrained peptides as PDCs against multiple targets of interest selected by Novartis.
Under the agreement, Novartis will have exclusive rights to the program peptides for radionuclide payloads/conjugates and certain small molecule payloads/conjugates, for both therapeutic and diagnostic uses. PeptiDream will receive R&D funds as well as future sales of any commercialized products resulting from the collaboration.
Using PeptiDream’s technology for target delivery of conjugated payloads and Novartis experience on working with PDCs, the partnership aims to bring a number of first-in-class and best-in-class therapeutics and their companion diagnostics to patients worldwide. (Source)
Hear more about the latest technological developments by other key Japanese biopharmaceutical players in our Biologics Manufacturing Japan.